In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a ...

In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price ...

(Reuters) - Johnson & Johnson (NYSE: JNJ) said on Monday it had filed a lawsuit against Samsung (KS: 005930) Bioepis for breaching its contract agreement with the drugmaker over the launch of a ...

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be competitive with other Crohn’s, colitis medicines in testing.

Bank Leumi (TASE: LUMI) led the market today, falling 1.02% on the day's biggest trading turnover. Bank Hapoalim (TASE: POLI) fell 1.37%, Mizrahi Tefahot Bank fell 0.53% and Israel Discount Bank (TASE ...

In particular, the third quarter of the fiscal year also saw record revenue and margins, with the gross margin improving by 1 ...

Teva and Sanofi's duvakitug showed promising results in a Phase 2b study for ulcerative colitis and Crohn's disease, with ...

Teva Pharmaceuticals and Alvotech have announced the US launch of the Selarsdi (ustekinumab-aekn) injection, a biosimilar to ...

Sanofi and Teva Pharmaceuticals have reported new outcomes from the randomised Phase IIb RELIEVE UCCD trial of human ...

This stock has stumbled, but long-term investors may want to lace up and run toward this dip before it sprints higher.

Bausch Health reported strong Q4 results with a 6.2% Y/Y revenue increase and positive net income, driving a 10% stock rally.